Karim R. Masri
YOU?
Author Swipe
View article: Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study Open
Objectives This 1-year long-term extension (LTE) study ( NCT04451772 ) followed the 48-week phase 2 SLEek study ( NCT03978520 ) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine…
View article: ABS1062 IMPACT OF CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB OR PLACEBO: RESULTS FROM THE PHASE 2 SLEek STUDY
ABS1062 IMPACT OF CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB OR PLACEBO: RESULTS FROM THE PHASE 2 SLEek STUDY Open
View article: POS0170 ACHIEVEMENT OF TREAT TO TARGET MEASURES WITH UPADACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PHASE 2 RANDOMIZED SLEek CLINICAL TRIAL RESULTS
POS0170 ACHIEVEMENT OF TREAT TO TARGET MEASURES WITH UPADACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PHASE 2 RANDOMIZED SLEek CLINICAL TRIAL RESULTS Open
View article: ABS0316 EFFICACY ACROSS BASELINE CHARACTERISTIC SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB: RESULTS FROM SLEek, A PHASE 2 RANDOMIZED CLINICAL TRIAL
ABS0316 EFFICACY ACROSS BASELINE CHARACTERISTIC SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH UPADACITINIB: RESULTS FROM SLEek, A PHASE 2 RANDOMIZED CLINICAL TRIAL Open
View article: Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review Open
Myositis, or idiopathic inflammatory myopathy, encompasses a group of autoimmune diseases with broad-spectrum clinical presentations, with a common presentation of muscle weakness and inflammation. The management of myositis presents signi…
View article: Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry Open
View article: Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis Open
Background Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly s…
View article: Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study Open
Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TN…
View article: Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting Open
View article: Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry Open
Objective This real-world analysis assessed baseline demographics/characteristics and treatment patterns/effectiveness in patients with rheumatoid arthritis (RA) initiating tofacitinib (TOF) in the US CorEvitas RA Registry. Methods The pri…
View article: Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study Open
This study supports leflunomide as co-therapy to pegloticase in uncontrolled gout patients. Heterogeneity and high comorbidity burden in uncontrolled gout patients makes having a variety of immunomodulators options important.
View article: Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response Open
Purpose of Review Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain ser…
View article: The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review Open
Published reports suggest that immunomodulation co-therapy has the potential to markedly improve pegloticase responder rates in patients with uncontrolled gout.
View article: THU0434 LEFLUNOMIDE CO-THERAPY WITH PEGLOTICASE IN UNCONTROLLED GOUT
THU0434 LEFLUNOMIDE CO-THERAPY WITH PEGLOTICASE IN UNCONTROLLED GOUT Open